PMID- 33640577 OWN - NLM STAT- MEDLINE DCOM- 20220131 LR - 20220503 IS - 1879-0593 (Electronic) IS - 1368-8375 (Print) IS - 1368-8375 (Linking) VI - 116 DP - 2021 May TI - Risk groups of laryngeal cancer treated with chemoradiation according to nomogram scores - A pooled analysis of RTOG 0129 and 0522. PG - 105241 LID - S1368-8375(21)00064-6 [pii] LID - 10.1016/j.oraloncology.2021.105241 [doi] AB - OBJECTIVES: To develop nomograms predicting overall survival (OS), freedom from locoregional recurrence (FFLR), and freedom from distant metastasis (FFDM) for patients receiving chemoradiation for laryngeal squamous cell carcinoma (LSCC). MATERIAL AND METHODS: Clinical and treatment data for patients with LSCC enrolled on NRG Oncology/RTOG 0129 and 0522 were extracted from the RTOG database. The dataset was partitioned into 70% training and 30% independent validation datasets. Significant predictors of OS, FFLR, and FFDM were obtained using univariate analysis on the training dataset. Nomograms were built using multivariate analysis with four a priori variables (age, gender, T-stage, and N-stage) and significant predictors from the univariate analyses. These nomograms were internally and externally validated using c-statistics (c) on the training and validation datasets, respectively. RESULTS: The OS nomogram included age, gender, T stage, N stage, and number of cisplatin cycles. The FFLR nomogram included age, gender, T-stage, N-stage, and time-equivalent biologically effective dose. The FFDM nomogram included age, gender, N-stage, and number of cisplatin cycles. Internal validation of the OS nomogram, FFLR nomogram, and FFDM nomogram yielded c = 0.66, c = 0.66 and c = 0.73, respectively. External validation of these nomograms yielded c = 0.59, c = 0.70, and c = 0.73, respectively. Using nomogram score cutoffs, three risk groups were separated for each outcome. CONCLUSIONS: We have developed and validated easy-to-use nomograms for LSCC outcomes using prospective cooperative group trial data. CI - Copyright (c) 2021. Published by Elsevier Ltd. FAU - Awan, Musaddiq J AU - Awan MJ AD - Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, United States. Electronic address: mawan@mcw.edu. FAU - Gittleman, Haley AU - Gittleman H AD - Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, United States. FAU - Barnholtz-Sloan, Jill AU - Barnholtz-Sloan J AD - Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, United States. FAU - Machtay, Mitchell AU - Machtay M AD - Department of Radiation Oncology, Case Western Reserve University, Cleveland, OH, United States. FAU - Nguyen-Tan, Phuc Felix AU - Nguyen-Tan PF AD - Department of Radiation Oncology, Centre Hospitalier de l'Universite de Montreal Hopital Notre Dame, Montreal, Quebec, Canada. FAU - Rosenthal, David I AU - Rosenthal DI AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. FAU - Schultz, Christopher AU - Schultz C AD - Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, United States. FAU - Huth, Bradley J AU - Huth BJ AD - Department of Radiation Oncology, University of Cincinatti, Cincinatti, OH, United States; Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA, United States. FAU - Thorstad, Wade L AU - Thorstad WL AD - Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, United States. FAU - Frank, Steven J AU - Frank SJ AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. FAU - Kim, Harold AU - Kim H AD - Department of Radiation Oncology, Wayne State University, Detroit, MI, United States. FAU - Foote, Robert L AU - Foote RL AD - Department of Radiation Oncology, Mayo Clinic, Rochester, MN, United States. FAU - Lango, Miriam N AU - Lango MN AD - Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, United States. FAU - Shenouda, George AU - Shenouda G AD - Department of Radiation Oncology, McGill University Healthcare, Toronto, Ontario, Canada. FAU - Suntharalingam, Mohan AU - Suntharalingam M AD - Department of Radiation Oncology, University of Maryland, Baltimore, MD, United States. FAU - Harris, Jonathan AU - Harris J AD - NRG Oncology Statistics and Data Management Center, American College of Radiology, Philadelphia, PA, United States. FAU - Zhang, Qiang AU - Zhang Q AD - NRG Oncology Statistics and Data Management Center, American College of Radiology, Philadelphia, PA, United States. FAU - Le, Quynh-Thu AU - Le QT AD - Department of Radiation Oncology, Stanford University, Palo Alto, CA, United States. FAU - Yao, Min AU - Yao M AD - Department of Radiation Oncology, Case Western Reserve University, Cleveland, OH, United States. CN - NRG Oncology Group LA - eng GR - U10 CA180868/CA/NCI NIH HHS/United States GR - P30 CA015083/CA/NCI NIH HHS/United States GR - U24 CA180803/CA/NCI NIH HHS/United States GR - UG1 CA233163/CA/NCI NIH HHS/United States GR - U10 CA180822/CA/NCI NIH HHS/United States PT - Journal Article PT - Meta-Analysis PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20210225 PL - England TA - Oral Oncol JT - Oral oncology JID - 9709118 RN - Q20Q21Q62J (Cisplatin) SB - IM MH - Chemoradiotherapy MH - Cisplatin/administration & dosage MH - Humans MH - *Laryngeal Neoplasms/diagnosis/therapy MH - Neoplasm Recurrence, Local MH - Neoplasm Staging MH - *Nomograms MH - *Prognosis MH - Prospective Studies MH - Squamous Cell Carcinoma of Head and Neck/diagnosis/therapy PMC - PMC8144062 MID - NIHMS1683504 OTO - NOTNLM OT - Chemoradiation OT - Larynx Cancer OT - Nomograms OT - Prognostic Factors COIS- Conflicts of Interest The authors have no relevant conflicts of interest to disclose. EDAT- 2021/03/01 06:00 MHDA- 2022/02/01 06:00 PMCR- 2022/05/01 CRDT- 2021/02/28 20:31 PHST- 2020/06/11 00:00 [received] PHST- 2021/02/05 00:00 [revised] PHST- 2021/02/14 00:00 [accepted] PHST- 2021/03/01 06:00 [pubmed] PHST- 2022/02/01 06:00 [medline] PHST- 2021/02/28 20:31 [entrez] PHST- 2022/05/01 00:00 [pmc-release] AID - S1368-8375(21)00064-6 [pii] AID - 10.1016/j.oraloncology.2021.105241 [doi] PST - ppublish SO - Oral Oncol. 2021 May;116:105241. doi: 10.1016/j.oraloncology.2021.105241. Epub 2021 Feb 25.